Massachusetts Eye and Ear Infirmary

Managing repeat transplant failureWhen considering the Boston type 1 keratoprosthesis as the evidence-based procedure of choice for managing cornea graft failure, superior visual outcomes must be weighed against greater risk of sight-threatening complications.
Bascom Palmer takes top honors in Ophthalmology Times Best Programs SurveyAfter a seven-year hiatus, Ophthalmology Times resumed its Best Programs Survey this fall. While a few new names popped up on the list, Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, Miami, remained at the top of the Best Overall Program category, followed again by the Wilmer Eye Institute at the Johns Hopkins University School of Medicine, Baltimore. Number three in the overall list has a new name with Dean McGee Eye Institute at the University of Oklahoma, Oklahoma City—the first time that institute has appeared in the top category since the survey’s inception 20 years ago.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
Effective drug management of PVR remains unfulfilled goalThe bottom line about pharmaceutical management of proliferative vitreoretinopathy (PVR) is that many different drugs have been tried, but so far nothing has been proven effective for treating PVR or reducing its risk, said Demetrios G. Vavvas, MD, PhD, at the inaugural Retina World Congress.
Looking to long-range keratoprosthesis outcomesFindings from a single-surgeon consecutive series including 97 eyes with up to 12 years of follow-up provide realistic insights for corneal surgeons about long-term outcomes after implantation of the Boston keratoprosthesis type 1 (“Boston KPro”; Massachusetts Eye and Ear Infirmary). The information—which included analyses of visual acuity results, device retention rates, and complications associated with the permanent keratoprosthesis—was presented by Anthony J. Aldave, MD, at Cornea 2016.
Frozen, fresh corneal donor carriers yield similar clinical outcomesFive-year results from a study of the Boston keratoprosthesis type 1 implant suggest that frozen and fresh corneal donors offer similar clinical outcomes—with no significant differences in device retention, visual rehabilitation or complication rates.
Tablet-based tests putting detection of glaucoma at handAn iPad-based quick contrast sensitivity test had similar sensitivity and specificity to frequency-doubling technology.
Drug-delivery platforms offer more options and promise for cliniciansSeven glaucoma drug delivery companies reviewed the latest data on platforms